膀胱癌化疗药物增敏机制研究进展

doi:10.12092/j.issn.1009-2501.2019.09.015

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (9): 1060-1064.doi: 10.12092/j.issn.1009-2501.2019.09.015

膀胱癌化疗药物增敏机制研究进展

徐伟平¹，周维英^2,3,4

¹西南政法大学校医院，重庆 401120；²重庆医科大学药学院药理学教研室， ³药物代谢研究重庆市重点实验室，⁴重庆市生物化学与分子药理学实验室，重庆 400016

收稿日期:2019-03-01 修回日期:2019-06-07 出版日期:2019-09-26 发布日期:2019-09-26
通讯作者: 周维英，女，博士，教授，博士生导师，研究方向：抗肿瘤药物药理学。 E-mail：wyzhou0118@163.com
作者简介:徐伟平，女，本科，主管检验师，研究方向：肿瘤早期诊断。 E-mail：2191901433@qq.com
基金资助:
国家自然科学基金面上项目(81874100)

Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer

XU Weiping¹, ZHOU Weiying^2,3,4

¹Southwest University of Political Science and Law Hospital, Chongqing 401120, China; ² Department of Pharmacology, Chongqing Medical University, ³Chongqing Key Laboratory of Drug Metabolism，Chongqing 400016, China；⁴ Chongqing Laboratory of Biochemisty and Molecular Pharmacology,Chongqing 401120, China

Received:2019-03-01 Revised:2019-06-07 Online:2019-09-26 Published:2019-09-26

摘要/Abstract

摘要：

近年来化疗耐药严重制约着膀胱癌的治疗效果，术后复发率和转移率居高不下。因此，逆转膀胱癌化疗耐药性，寻找有效的化疗增敏靶点并探究其机制十分重要。目前临床上多采用经尿道膀胱肿瘤切除术，术后选择辅助化疗药物进行治疗，常用化疗药物包括顺铂、吉西他滨、阿霉素、表柔比星等。目前实现这些药物化疗增敏的靶点基因和分子在膀胱癌细胞中呈现不同的表达状态，且通过这些靶点实现增敏的机制也各有不同。本文将就膀胱癌化疗药物增敏靶点及机制的研究进展进行综述，以期为膀胱癌的化疗增敏探索新的思路。

关键词: 膀胱癌, 耐药, 化疗药物, 化疗增敏, 靶点

Abstract:

In recent years, chemoresistance has seriously restricted the therapeutic effect of bladder cancer, and the recurrence rate and metastasis rate remain high. Therefore, it is very important to reverse the resistance of bladder cancer to chemotherapy, and find more effective target of chemosensitizion and explore its mechanism. Transurethral resection of bladder tumors is commonly used in treatment of bladder cancer currently, and adjuvant chemotherapy drugs are utilized after operation. The most chemotherapy drugs used in bladder cancer include cisplatin, gemcitabine, adriamycin and epirubicin. At present, the target genes and molecules for enhancing chemosensitivity of these drugs display various expression states in bladder cancer cells, and the mechanisms for enhancing chemosensitivity through these targets are also different. In this paper, we will review the research progress of target and mechanism of chemosensitizing drugs for bladder cancer, and explore new ideas for chemosensitizion of bladder cancer.

Key words: bladder cancer, drug resistance, chemotherapy drugs, chemotherapy sensitization, target

中图分类号:

R737
R69

徐伟平，周维英. 膀胱癌化疗药物增敏机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1060-1064.

XU Weiping, ZHOU Weiying. Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1060-1064.

参考文献

［1］Rieger C, Huebner D, Temme A, et al. Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells［J］. Int J Oncol, 2015,47(3):1121-1130.
［2］Gan Y, He L, Yao K, et al. Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling［J］. Oncol Lett, 2017,14(6):6463-6470.
［3］Li CC, Yang JC, Lu MC, et al.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer［J］. Oncotarget, 2016 ,7(2):1947-1959.
［4］Angell JE, Lindner DJ, Shapiro PS, et al. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach［J］. J Biol Chem, 2000，275(43):33416-33426.
［5］Ni F, Yan CY, Zhou S, et al. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation［J］. Cancer Chemother Pharmacol, 2018，82(4):593-605.
［6］Feng SQ, Zhang XY, Fan HT, et al. Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells［J］. Neoplasma, 2018，65(6):925-932.
［7］Yan Z, Jiang J, Li F, et al. Adenovirus-mediated LRIG1 expression enhances the chemosensitivityof bladder cancer cells to cisplatin［J］. Oncol Rep, 2015，33(4):1791-1798.
［8］Chen J, Wang L, Tang Y, et al.Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy［J］. J Exp Clin Cancer Res, 2016，35:2.
［9］Zhou J, Dai W, Song J. miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT［J］. Biochem Biophys Res Commun, 2016，470(2):445-452.
［10］Zhang X, Zhang Y, Liu X, et al. MicroRNA-203 Is a prognostic indicator in bladder cancer and enhances chemosensitivity to cisplatin via apoptosis by targeting Bcl-w and Survivin［J］. PLoS One, 2015，10(11):e0143441.
［11］Lei Y, Li B, Tong S, et al. MiR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells［J］. PLoS One, 2015，10(2):e0117809.
［12］Vinall RL, Ripoll AZ, Wang S, et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status［J］. Int J Cancer, 2012，130(11):2526-2538.
［13］Lei Y, Hu X, Li B, et al. MiR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro［J］. Med Sci Monit, 2014，20:1850-1857.
［14］Cozzi PJ, Bajorin DF, Tong W, et al.Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs［J］. Clin Cancer Res, 1999，5(9):2629-2637.
［15］Behnsawy HM, Miyake H, Kusuda Y, et al. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells ［J］. Urol Oncol, 2013，31(6):843-848.
［16］Muramaki m, So A, Hayashi N, et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin ［J］. BJU Int, 2009 ，103(3):384-390.
［17］Kraemer K, Fuessel S, Meye A. Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines［J］. Methods Mol Biol, 2007，405:9-22.
［18］Fuessel S, Herrmann J, Ning S, et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA［J］. CancerLett, 2006，232(2):243-254.
［19］Nordentoft I, Dyrskj TL, Bdker JS, et al. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladdercancer［J］. BMC Cancer, 2011，11:135.
［20］Brummelkamp TR, Nijman SM, Dirac AM, et al. Loss of cylindromatosis tumour suppressor inhibits apoptosis by activating NF-B［J］. Nature, 2003 ，424(6950):797-801.
［21］Alameda JP, Fernandez-acenero MJ, Moreno-maldonado R, et al. CYLD regulates keratinocyte, differentiation and skin cancer progression in humans［J］. Cell Death Dis, 2011, 2: e208.
［22］Kuphal S, Shaw-hallgren G, Eberl M, et al. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma［J］. Oncogene, 2011, 30(44): 4523-4530.
［23］Yin L, Liu S, Li C, et al. CYLD downregulates Livin and synergistically improves gemcitabinechemosensitivity and decreases migratory/invasive potential in bladdercancer: the effect is autophagy-associated［J］. Tumour Biol, 2016，37(9):12731-12742.
［24］Chen JF, Yu BX, Yu R, et al. Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to epirubicin by promoting G1/S arrest and apoptosis［J］. Oncol Rep, 2017，37(2):721-728.
［25］Hu H, Han HY, Wang YL, et al. The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells［J］. Oncol Rep, 2009 ，21(4):1053-1059.
［26］Lu J, Luo JH, Pang J, et al. Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladdercancer cells to epirubicin in vitro［J］. Mol Med Rep, 2012，6(5):1133-1139.
［27］Romanova TV, Kotova SA, Amerik AIu，et al.ATP dependent protease La (lon) from escherichia coli［J］. Bioorg Khim，1994，20(2):114-125.
［28］Ondrovicova G, Liu T, Singh K, et al. Cleavage site selection within a folded substrate by the ATP dependent lon protease［J］. J Biol Chem, 2005， 280(26): 25103-25110.
［29］Liu Y, Lan L, Huang K, et al. Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladdercancer: potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer［J］. Oncotarget, 2014，5(22):11209-11224.
［30］Smolensky D, Rathore K, Cekanova M. Phosphatidylinositol-3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro［J］. BMC Cancer, 2015，15:927.
［31］Kanai K, Kikuchi E, MIkami S, et al. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in humanbladder cancer cells in vitro and in vivo［J］. Cancer Sci, 2010，101(1):216-223.
［32］Zhang HH, Huang B, Cao YH, et al. Role of 5-Aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells［J］. Oncol Lett, 2017，14(5):5652-5656.

[1]	姜道利, 丑晓华, 刘志东, 李薇, 张波, 许桑, 谈德斐, 方翼, 吕冬梅, 王涛. 头孢他啶阿维巴坦治疗多重耐药革兰阴性菌感染的真实世界研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 1008-1017.
[2]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[3]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[4]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[5]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[6]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[7]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[8]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[9]	周欢, 徐铭, 李波, 刘春英, 王淳. PI3K/Akt/FOXO3a信号通路介导的保护性自噬参与肺腺癌获得性顺铂耐药表型重塑[J]. 中国临床药理学与治疗学, 2022, 27(9): 961-970.
[10]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[11]	叶小弟, 缪云萍, 陈爱瑛, 程敏, 田雪君, 郑高利. 裸鼠原位非肌层浸润性膀胱癌模型的优选及验证[J]. 中国临床药理学与治疗学, 2022, 27(4): 473-480.
[12]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[13]	陈云杰, 周旋, 张元斌, 王旭, 林珠, 朱素燕. ErbB2在心脏疾病中作用的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(10): 1182-1189.
[14]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[15]	余赛红, 郑晓亮, 蒲依依, 颜冬梅, 王孝举, 于洁. 通过核糖核苷酸还原酶M2逆转肝癌细胞对5-氟尿嘧啶耐药[J]. 中国临床药理学与治疗学, 2021, 26(7): 729-737.

膀胱癌化疗药物增敏机制研究进展

Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价